Kilitch Drugs (KILITCH) | Stock Overview & Key Data
Kilitch Drugs Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹500.00 on July 15, 2025
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Dec 31, 2025
Annual Income Flow
2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Kilitch Drugs
KILITCH
|
5.57B Small-cap | -1.11% | 16.16% | 12.55% | 3.84% | -0.60% | -15.49% | 72.82% | 131.81% | 1,009.43% | 521.22% | 188.64% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | -2.77% | -1.84% | 2.13% | -0.53% | 4.00% | 7.25% | 79.99% | 166.96% | 144.01% | 669.48% | 2,278.32% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | -3.26% | -1.31% | 2.02% | 1.80% | 2.98% | 0.83% | 89.86% | 56.44% | 484.44% | 1,625.50% | 9,907.51% |
|
Sun Pharma Advanced
SPARC
|
46.75B Small-cap | -13.30% | 46.20% | 62.20% | 26.84% | 51.26% | 14.56% | 13.10% | -5.14% | -23.02% | 148.11% | -27.03% |
|
Innova Captab
INNOVACAP
|
41.43B Small-cap | 2.24% | 2.13% | 29.82% | 21.15% | 16.79% | -3.19% | 57.07% | 57.07% | 57.07% | 57.07% | 57.07% |
|
Gujarat Themis
GUJTHEM
|
35.41B Small-cap | 7.42% | 6.10% | 33.40% | -1.19% | -10.34% | 31.69% | 84.69% | 84.69% | 84.69% | 84.69% | 84.69% |
Ownership & Short Interest
Calculate Your Kilitch Drugs Investment Returns
Long-Term Investment Performance Analysis
Kilitch Drugs stock price in May 2016 was ₹16.44, A ₹1,000.00 lump sum investment in Kilitch Drugs made 10 years ago would be worth approximately ₹10,502.43 today, representing a exceptional return of 950.24%. This translates to an annualized return (CAGR) of 26.48%.
10 Years Investment Scenario (May 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is KILITCH's 52-week high and low?
- In the last 52 weeks, Kilitch Drugs reached a high of ₹250.00 (on N/A) and a low of ₹117.25 (on March 30, 2026).
- What is the market cap and P/E ratio for KILITCH?
- Curious about Kilitch Drugs's size and valuation? Its market capitalization stands at 5.57B. When it comes to valuation, the P/E ratio (trailing twelve months) is 20.30, and the forward P/E (looking ahead) is 10.42.
- Does KILITCH pay dividends? If so, what's the yield?
- As for dividends, Kilitch Drugs isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Kilitch Drugs's main competitors or similar companies to consider before investing?
When looking at Kilitch Drugs, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.25% 79.99% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic 0.83% 89.86% Sun Pharma Advanced
SPARC46.75B Healthcare Drug Manufacturers - Specialty & Generic 14.56% 13.10% Innova Captab
INNOVACAP41.43B Healthcare Drug Manufacturers - Specialty & Generic -3.19% 57.07% Gujarat Themis
GUJTHEM35.41B Healthcare Drug Manufacturers - Specialty & Generic 31.69% 84.69% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Kilitch Drugs (India) Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Kilitch Drugs's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 13.32%, the Debt to Equity ratio from the most recent quarter is 31.65, and its Gross Profit Margin stands at 42.60%.
- What is the recent revenue and earnings growth for KILITCH?
- Looking at Kilitch Drugs's growth, its revenue over the trailing twelve months (TTM) was INR2B. Compared to the same quarter last year (YoY), quarterly revenue grew by -4.20%, and quarterly earnings saw a YoY growth of -25.60%.
- How much of KILITCH stock is held by insiders and institutions?
- Wondering who owns Kilitch Drugs stock? Company insiders (like executives and directors) hold about 72.22% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.